These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30972160)

  • 1. Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy.
    Li N; Xie X; Hu Y; He H; Fu X; Fang T; Li C
    Am J Transl Res; 2019; 11(3):1255-1269. PubMed ID: 30972160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect.
    Bjørnstad R; Reiten IN; Knudsen KS; Schjøtt J; Herfindal L
    Int J Pharm; 2022 Dec; 629():122379. PubMed ID: 36370997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines.
    Duarte JA; Gomes ER; De Barros ALB; Leite EA
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
    Ahmed KS; Shan X; Mao J; Qiu L; Chen J
    Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
    Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
    Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumour activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma.
    Alkreathy HM; Alkhatib MH; Al Musaddi SA; Balamash KSA; Osman NN; Ahmad A
    Clin Exp Pharmacol Physiol; 2019 May; 46(5):496-505. PubMed ID: 30724380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization, and Co-delivery of cisplatin and doxorubicin-loaded liposomes to enhance anticancer Activities.
    Bahrami Parsa M; Tafvizi F; Chaleshi V; Ebadi M
    Heliyon; 2023 Oct; 9(10):e20657. PubMed ID: 37818003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis.
    Negrea G; Rauca VF; Meszaros MS; Patras L; Luput L; Licarete E; Toma VA; Porfire A; Muntean D; Sesarman A; Banciu M
    Front Pharmacol; 2022; 13():870347. PubMed ID: 35450036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy.
    Zhu S; Li X; Luo Z; Ding M; Shi S; Zhang T
    Drug Deliv Transl Res; 2024 Mar; 14(3):718-729. PubMed ID: 37679600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
    Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
    Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.
    Lin Q; Mao KL; Tian FR; Yang JJ; Chen PP; Xu J; Fan ZL; Zhao YP; Li WF; Zheng L; Zhao YZ; Lu CT
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):269-80. PubMed ID: 26666650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.